跳到正文
原文
MedPage Today·· 9 天前精选AI 评分65

生物工程肝脏系统在急性肝衰竭一期临床试验中通过安全性测试

Bioengineered Liver System Passes Safety Test in Phase I Trial

AI 导读

生物工程肝脏系统在一期临床试验中显示安全,五名患者中有三人治疗后21天存活,且有改善脑病和降低血管加压药需求的迹象。

推荐理由

展示了生物工程肝脏系统的初步安全性和潜在疗效,为急性肝衰竭治疗提供了新希望。

正文 · 原文

— The miroliverELAP also showed signs of efficacy in patients with syndromes of liver failure

November 10, 2026 • 3 min read

A single-use bioengineered liver paired with an extracorporeal blood circuit that replicates key functions of a human liver was shown to be safe among patients with syndromes of liver failure in a small phase I trial.

There were no serious or unexpected adverse events (AEs) related to the miroliverELAP system, while every patient was still alive after the scheduled 48 hours of treatment, reported Christopher J. Danford, MD, of Intermountain Health in Salt Lake City, at the American Association for the Study of Liver Diseases annual meeting in Denver.

In addition, the system demonstrated signs of efficacy, as there was an improvement in encephalopathy and reductions in vasopressor requirements during the course of treatment.

While none of the patients in the study were transplant candidates, "many of them would have been potentially transplantable by the end of treatment, and based on those results, we're moving forward with our phase II and III clinical trial," Danford noted.

Syndromes of liver failure -- fulminant hepatic failure, acute alcoholic hepatitis (AAH), and acute-on-chronic liver failure (ACLF) -- are devastating conditions for which there's no good treatment other than liver transplant. Due to the lack of transplantable livers and the rapid onset of acute liver failure, a significant number of patients die before getting access to a liver transplant.

"The hope is that an external bioengineered liver may provide some support that either bridges the patient to recovery or transplant," Danford said. "However, there are no previous studies in humans involving a bioengineered liver."

The FDA granted a Regenerative Medicine Advanced Therapy designation to the miroliverELAP system for the treatment of acute liver failure in April. As described by its maker in a press release, the bioengineered liver is manufactured "by seeding a decellularized porcine liver scaffold with allogeneic human endothelial cells and human liver cells isolated from donated human livers." These donated livers are not considered suitable for transplantation and are provided by organ procurement organizations.

This study included seven critically ill patients who initiated therapy, five of whom completed the planned therapy (ranging in age from 27 to 43).

The primary etiology was AAH in four patients, and ACLF in the fifth, with a mean Model for End-Stage Liver Disease (MELD) score of 36.

Inclusion criteria included a MELD score ≥20, an International Normalized Ratio (INR) ≥2.0, and a West Haven hepatic encephalopathy (HE) grade of 1-3, while patients were excluded if eligible for transplantation.

Primary endpoints were serious AEs attributable to the system, and survival for the duration of the therapy. Secondary endpoints included 21-day post-treatment survival.

Three of the five patients who completed therapy were alive 21 days post-treatment.

There were a total of 42 AEs, with 17 occurring during treatment (11 possibly or probably related to treatment). System-related AEs among the full seven patients included grade 2-3 thrombocytopenia (four patients), anemia (three patients), bleeding (two patients), hypotension (two patients), and worsening lactic acidosis (one patient).

Twenty-five AEs occurred after therapy, one of which, a gastrointestinal bleed, was deemed possibly related to treatment. There were six serious AEs after therapy, including five deaths related to liver disease progression.

While this was primarily a safety study, "there were some promising [efficacy] signs," Danford noted.

Of the five patients who completed treatment, four experienced improvement in encephalopathy, with improvement sustained 48 hours post-treatment. In addition, while three of the five patients were on significant vasopressor therapy at baseline, all five were either off vasopressors or had their requirements reduced by 75% at the completion of the trial.

来源:MedPage Today · medpagetoday.com